BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information Letter on Lynparza® 50 mg hard capsules (active ingredient olaparib): discontinuation of production at the end of 2021

2021.06.29

Active substance: olaparib

AstraZeneca informs that the production of Lynparza® 50 mg hard capsules (active ingredient: olaparib) will be discontinued at the end of 2021.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 83KB, File is accessible